Distribution of ESBLs, AmpC β-lactamases and Carbapenemases Among Enterobacteriaceae Isolates Causing Intra-abdominal and Urinary Tract Infections in the Asia-Pacific Region During 2008-14: Results from the Study for Monitoring Antimicrobial...
Overview
Authors
Affiliations
Objectives: To investigate the antimicrobial resistance and assess the molecular characteristics of β-lactamases (ESBLs, AmpC β-lactamases and carbapenemases) among Enterobacteriaceae isolates that caused intra-abdominal infections (IAIs) in patients hospitalized in the Asia-Pacific region during 2008-14.
Methods: Multiplex PCR was used to detect the specific types of β-lactamase in 2893 isolates with MICs of ertapenem >0.5 mg/L. In-hospital acquisition times for most isolates were also delineated.
Results: Among 2728 (94.3%) isolates proven with β-lactamase production, the rates of non-susceptibility to imipenem were low (average = 7.9%) among IAI Enterobacteriaceae isolates from all Asia-Pacific countries except Vietnam (17.7%) and the Philippines (10.2%). A stepwise and significant increase in annual rates of carbapenemase production among these isolates was noted. CTX-M-15 and CTX-M-14 were the dominant ESBL variants in most IAI Enterobacteriaceae species. The most abundant AmpC β-lactamase variants were bla among isolates of Escherichia coli and bla among isolates of Klebsiella pneumoniae. In addition, the IAI Enterobacteriaceae isolates harbouring a bla or bla allele were associated with high community-acquired rates (38.0% and 42.6%, respectively). AmpC ACT and MIR variants were mostly detected in Enterobacter species. The bla-harbouring isolates of E. coli, K. pneumoniae and Enterobacter cloacae were most commonly identified among IAI isolates from Vietnam and the Philippines. Also of note, bla-harbouring IAI Enterobacteriaceae isolates were detected exclusively in Vietnam.
Conclusions: The high resistance burden in Vietnam and the Philippines warrants aggressive control policies to combat the worsening trend in antimicrobial resistance among Enterobacteriaceae species causing IAIs.
Que A, Tran A, Trang T, Tran T, Bui N, Lai C Ther Adv Infect Dis. 2025; 12:20499361251315346.
PMID: 40027950 PMC: 11869312. DOI: 10.1177/20499361251315346.
Shrestha R, Shrestha D, Sah A, Thapa A, Shrestha N, Raya G JAC Antimicrob Resist. 2024; 6(2):dlae035.
PMID: 38476771 PMC: 10928669. DOI: 10.1093/jacamr/dlae035.
Padovani M, Bertelli A, Corbellini S, Piccinelli G, Gurrieri F, De Francesco M Antibiotics (Basel). 2023; 12(4).
PMID: 37107147 PMC: 10135176. DOI: 10.3390/antibiotics12040785.
Wang N, Zhan M, Wang T, Liu J, Li C, Li B Infect Drug Resist. 2023; 16:1279-1295.
PMID: 36910515 PMC: 9994629. DOI: 10.2147/IDR.S401807.
Bourles A, Kainiu M, Ukeiwe D, Brunet N, Despaux C, Biron A Antibiotics (Basel). 2023; 12(2).
PMID: 36830303 PMC: 9952050. DOI: 10.3390/antibiotics12020392.